Median Technologies and CMIC Holdings (CMIC) announced a collaborative agreement for comprehensive clinical trial services. Together, Median and CMIC will leverage complementary expertise to help biopharmaceutical companies accelerate oncology drug development in Japan, China and East Asia.
The agreement came following an onsite audit at Median's headquarters in France late last year. Through the collaboration, CMIC will access Median's imaging technologies, services and imaging expertise. It also extends Median's access to biopharmaceutical sponsors with clinical trials in Asia. Median and CMIC will promote and deliver their combined services to speed oncology drug development and provide therapies to patients.
"The agreement with CMIC, a leading CRO in Asia, is a landmark event for Median Technologies. With our enhanced technology and in-depth expertise in oncology medical image interpretation and management, we complement their offering in a key area of growth." said Nicholas Campbell, Chief Commercial Officer at Median Technologies. "We have been accelerating our expansion in Asia with the opening of our subsidiary in Shanghai and recent key new hires in Japan and China. Our CMIC collaboration strengthens our efforts and extends our footprint for our clinical trial business in the fast-growing Asian market. We look forward to a fruitful partnership.”